Pfizer Polska You have been appointed at the head of Pfizer Poland last December. 2010 is a hot year for the group – even very hot for some of the top management – What has been the most challenging thing for you to deal with in this first year in Poland? The…
Novo Nordisk Pharma Sp. z.o.o Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies in the many unmet, local medical needs. What are the main specificities of the Polish market in your view and…
PharmaExpert What is PharmaExpert’s role in the Polish pharmaceutical industry? The information that PharmaExpert gathers enables us to give good insight about the evolution of the pharmacists market, the evolution of the prices in the pharma landscape, and of the level of reimbursement, among others. PharmaExpert created a model of explanation…
Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…
Malaysian Biotech Organisation (MBIO) Kebangsaan Malaysia (UKM). Singapore and Taiwan are known for their high level of basic research and their focus on Biotechnology. Philip Yeo, Chairman of Spring Singapore told us that Biomedical science was an undisputed pillar of Singapore’s economy. How do you situate Malaysia in terms of R&D compared to other…
Cegedim Strategic Data Malaysia Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market research how can CSD find a space within this picture and what strategies does it employ to stay ahead of…
Top Institute Pharma There is a very interesting history behind the origins of Top Institute Pharma (TI Pharma) as it aligned the interests of both the World Health Organization (Priority Medicines) and the EU’s Lisbon Strategy. Lisbon’s goal in 2000 was to transform the EU into the most powerful knowledge economy by 2010…
Vifor Pharma UK Ltd You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and the organization in the year since Vifor Pharma UK came into being? I was actually the first employee of Vifor…
Norgine Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor is that I had had a lot of experience with larger pharmaceutical companies, like Schering-Plough—it was fascinating, but one of…
HAL Allergy Group Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and proud history in the Netherlands dating back more than 50 years to its origins in Haarlem. What have been the…
Bristol-Myers Squibb UK Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining BMS 4 years ago and even before spending those twenty years with GSK, I had already worked for Sanofi-Aventis for…
Ranbaxy (UK) Ltd. (RUKL) You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish it from your previous position? Obviously there are quite a lot of challenges in moving from one continent to another,…
See our Cookie Privacy Policy Here
